HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040

Reuters

2025/11/10

HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040

HCW Biologics Inc. has announced updated preclinical data for its lead product candidate, HCW11-040, a second-generation, tetra-valent pembrolizumab-based immune checkpoint inhibitor. The data were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC2025), held from November 5 to 9, 2025. HCW11-040 is a multi-functional fusion protein constructed using the company's TRBC platform and includes IL-15 and IL-7 domains as well as a TGF-β trap. Preclinical results demonstrated that HCW11-040 has PD-1/PD-L1 blocking activity comparable to pembrolizumab and showed enhanced expansion and activation of memory T cells, as well as improved anti-tumor activity against pancreatic cancer and leukemia cells in organoid models, without inducing excessive inflammatory responses. The company indicated plans to advance further IND-enabling studies for HCW11-040.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582873134"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582873134\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582873134?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582873134","market":"fut","top_or_hot":-1,"title":"HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/HCWB\">HCW Biologics Inc.</a> has announced updated preclinical data for its lead product candidate, HCW11-040, a second-generation, tetra-valent pembrolizumab-based immune checkpoint inhibitor. The data were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC2025), held from November 5 to 9, 2025. HCW11-040 is a multi-functional fusion protein constructed using the company's TRBC platform and includes IL-15 and IL-7 domains as well as a TGF-β trap. Preclinical results demonstrated that HCW11-040 has PD-1/PD-L1 blocking activity comparable to pembrolizumab and showed enhanced expansion and activation of memory T cells, as well as improved anti-tumor activity against pancreatic cancer and leukemia cells in organoid models, without inducing excessive inflammatory responses. The company indicated plans to advance further IND-enabling studies for HCW11-040.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-10 20:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/HCWB\">HCW Biologics Inc.</a> has announced updated preclinical data for its lead product candidate, HCW11-040, a second-generation, tetra-valent pembrolizumab-based immune checkpoint inhibitor. The data were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC2025), held from November 5 to 9, 2025. HCW11-040 is a multi-functional fusion protein constructed using the company's TRBC platform and includes IL-15 and IL-7 domains as well as a TGF-β trap. Preclinical results demonstrated that HCW11-040 has PD-1/PD-L1 blocking activity comparable to pembrolizumab and showed enhanced expansion and activation of memory T cells, as well as improved anti-tumor activity against pancreatic cancer and leukemia cells in organoid models, without inducing excessive inflammatory responses. The company indicated plans to advance further IND-enabling studies for HCW11-040.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL79Kr1s:1","article_id":"2582873134","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582873134","pubTimestamp":1762776296,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HCW Biologics Inc. has announced updated preclinical data for its lead product candidate, HCW11-040, a second-generation, tetra-valent pembrolizumab-based immune checkpoint inhibitor. The data were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer , held from November 5 to 9, 2025. HCW11-040 is a multi-functional fusion protein constructed using the company's TRBC platform and includes IL-15 and IL-7 domains as well as a TGF-β trap. Preclinical results demonstrated that HCW11-040 has PD-1/PD-L1 blocking activity comparable to pembrolizumab and showed enhanced expansion and activation of memory T cells, as well as improved anti-tumor activity against pancreatic cancer and leukemia cells in organoid models, without inducing excessive inflammatory responses. The company indicated plans to advance further IND-enabling studies for HCW11-040.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HCWB":"HCW Biologics Inc.","BK4539":"次新股"},"translate_title":"HCW Biologics公布下一代免疫检查点抑制剂HCW11-040有希望的临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCWB":0.9},"content_text":"HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040\n    \n\nHCW Biologics Inc. has announced updated preclinical data for its lead product candidate, HCW11-040, a second-generation, tetra-valent pembrolizumab-based immune checkpoint inhibitor. The data were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC2025), held from November 5 to 9, 2025. HCW11-040 is a multi-functional fusion protein constructed using the company's TRBC platform and includes IL-15 and IL-7 domains as well as a TGF-β trap. Preclinical results demonstrated that HCW11-040 has PD-1/PD-L1 blocking activity comparable to pembrolizumab and showed enhanced expansion and activation of memory T cells, as well as improved anti-tumor activity against pancreatic cancer and leukemia cells in organoid models, without inducing excessive inflammatory responses. The company indicated plans to advance further IND-enabling studies for HCW11-040.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}